Evidence map›Paper›PMID 40299553›Full record

ArticleThe Journal of clinical investigation2025

OCA-B promotes pathogenic maturation of stem-like CD4+ T cells and autoimmune demyelination.

Erik P Hughes, Amber R Syage, Elnaz Mirzaei Mehrabad, Thomas E Lane, Benjamin T Spike, Dean Tantin

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Erik P HughesDepartment of Pathology.
Amber R SyageDepartment of Pathology.
Elnaz Mirzaei MehrabadHuntsman Cancer Institute, and.
Thomas E LaneDepartment of Neurobiology and Behavior, School of Biological Sciences, University of California, Irvine, California, USA.
Benjamin T SpikeHuntsman Cancer Institute, and.
Dean TantinDepartment of Pathology.

Funding

Training Program in Microbial PathogenesisT32AI055434 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MULVEY, MATTHEW A, PLANELLES, VICENTE · 2004 to 2025
$6.0M
Defining mechanisms of disease and repair in a viral model of multiple sclerosisR35NS116835 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Thomas E Lane · 2020 to 2026
$5.0M
Role of Transcription Coactivator OCA-B in Gene Poising and Immunological MemoryR01AI100873 · NIAID · UNIVERSITY OF UTAH · PI TANTIN, DEAN · 2013 to 2022
$3.8M
Targeting OCA-B in multiple sclerosisR01AI162929 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI DEAN TANTIN · 2022 to 2026
$2.0M
The Neuroimmunology Training Program at the University of UtahT32NS115664 · NINDS · UNIVERSITY OF UTAH · PI O'CONNELL, RYAN M, WILCOX, KAREN S · 2020 to 2024
$988k
NIAID NIH HHS R01 AI100873NIAID NIH HHS R01 AI162929NIAID NIH HHS T32 AI055434NINDS NIH HHS R35 NS116835NINDS NIH HHS T32 NS115664
6 · The paper itself

Abstract

Stem-like T cells selectively contribute to autoimmunity, but the activities that promote their pathogenicity are incompletely understood. Here, we identify the transcription coregulator OCA-B as a driver of the pathogenic maturation of stem-like CD4+ T cells to promote autoimmune demyelination. Using 2 human multiple sclerosis (MS) datasets, we show that POU2AF1, the gene encoding OCA-B, is elevated in CD4+ T cells from patients with MS. We show that T cell-intrinsic OCA-B loss protects mice from experimental autoimmune encephalomyelitis (EAE) while preserving responses to viral CNS infection. In EAE models driven by antigen re-encounter, OCA-B deletion nearly eliminates CNS infiltration, proinflammatory cytokine production, and clinical disease. OCA-B-expressing CD4+ T cells of mice primed with autoantigen express an encephalitogenic gene program and preferentially confer disease. In a relapsing-remitting EAE model, OCA-B loss protects mice specifically at relapse. During remission, OCA-B promotes the expression of Tcf7, Slamf6, and Sell in proliferating CNS T cell populations. At relapse time points, OCA-B loss results in both the accumulation of an immunomodulatory CD4+ T cell population expressing Ccr9 and Bach2, and loss of proinflammatory gene expression from Th17 cells. These results identify OCA-B as a driver of pathogenic CD4+ T cells.

Indexed as

CD4-Positive T-LymphocytesEncephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisStem CellsAnimalsFemaleHumansMiceMice, KnockoutAutoimmunityImmunologyMultiple sclerosisT cells

Identifiers

PMID40299553
PMCPMC12208553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.